The BioMedWire Podcast

AUSTIN, Texas, August 27, 2025 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features John Climaco, CEO of CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system.

To begin the interview, Climaco explained the devastating nature of glioblastoma and CNS Pharmaceuticals’ commitment to changing the outlook for patients facing this aggressive brain cancer.

“The problem for patients and clinicians in the space is that the cancers take place in the brain behind the blood-brain barrier, which is this very specialized network of cells that prevents otherwise helpful drugs from reaching the site of the cancer.… We believe that is the reason why a cancer like glioblastoma remains one of the two greatest unmet needs in oncology today, the other being pancreatic cancer… There is no cure. Patients have very little hope. Our mission is to change that completely, and we think we have the drugs to do it.”

Reflecting on the company’s response to the berubicin trial, he described how CNS Pharmaceuticals maintained its momentum and repurposed its clinical infrastructure to accelerate the development of a second promising candidate.

“When you have a drug development company, you’ve got to realize that 90% of oncology drug trials fail. Those are the odds that you’re facing… That doesn’t dissuade us at all, because we know these drugs work. We have to prove that; that is our job. So, when we pivoted from our berubicin study to our TPI 287 program, we didn’t miss a beat. We have repurposed all of the work that we did to develop a global clinical network for berubicin over to our TPI program. We really just seamlessly moved forward on that.”

Looking ahead, Climaco outlined the company’s broader ambitions and made the case for its potential in underserved cancer markets.

“When you look at the opportunities in the space that a drug like berubicin or TPI 287 could have, not just in the primary brain cancer space, but in the metastatic space, in triple-negative breast cancer – where 40% of patients have a metastasis to the brain – the multiple and the size of the potential market for these drugs is absolutely enormous… We have demonstrated what I believe is absolutely world-class operational expertise and the ability to bring a trial through to completion on time and on budget. We’ll do it again with TPI, and we hope that we’ll have a positive result and be on our way to a drug approval.

Join IBN’s Stuart Smith and John Climaco, CEO of CNS Pharmaceuticals, to learn more about the company’s vision, clinical programs, and unwavering focus on advancing treatment for brain cancer patients.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.

The company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date TPI 287 appears have both an excellent safety profile and high tolerability among patients.

For more information, please visit www.CNSPharma.com, and connect with the company on X, Facebook, and LinkedIn.

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

AUSTIN, Texas, August 27, 2025 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features John Climaco, CEO of CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system.

To begin the interview, Climaco explained the devastating nature of glioblastoma and CNS Pharmaceuticals’ commitment to changing the outlook for patients facing this aggressive brain cancer.

“The problem for patients and clinicians in the space is that the cancers take place in the brain behind the blood-brain barrier, which is this very specialized network of cells that prevents otherwise helpful drugs from reaching the site of the cancer.… We believe that is the reason why a cancer like glioblastoma remains one of the two greatest unmet needs in oncology today, the other being pancreatic cancer… There is no cure. Patients have very little hope. Our mission is to change that completely, and we think we have the drugs to do it.”

Reflecting on the company’s response to the berubicin trial, he described how CNS Pharmaceuticals maintained its momentum and repurposed its clinical infrastructure to accelerate the development of a second promising candidate.

“When you have a drug development company, you’ve got to realize that 90% of oncology drug trials fail. Those are the odds that you’re facing… That doesn’t dissuade us at all, because we know these drugs work. We have to prove that; that is our job. So, when we pivoted from our berubicin study to our TPI 287 program, we didn’t miss a beat. We have repurposed all of the work that we did to develop a global clinical network for berubicin over to our TPI program. We really just seamlessly moved forward on that.”

Looking ahead, Climaco outlined the company’s broader ambitions and made the case for its potential in underserved cancer markets.

“When you look at the opportunities in the space that a drug like berubicin or TPI 287 could have, not just in the primary brain cancer space, but in the metastatic space, in triple-negative breast cancer – where 40% of patients have a metastasis to the brain – the multiple and the size of the potential market for these drugs is absolutely enormous… We have demonstrated what I believe is absolutely world-class operational expertise and the ability to bring a trial through to completion on time and on budget. We’ll do it again with TPI, and we hope that we’ll have a positive result and be on our way to a drug approval.

Join IBN’s Stuart Smith and John Climaco, CEO of CNS Pharmaceuticals, to learn more about the company’s vision, clinical programs, and unwavering focus on advancing treatment for brain cancer patients.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.

The company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date TPI 287 appears have both an excellent safety profile and high tolerability among patients.

For more information, please visit www.CNSPharma.com, and connect with the company on X, Facebook, and LinkedIn.

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

AUSTIN, Texas, August 8, 2025 – via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas,” featuring Soligenix Inc. (NASDAQ: SNGX).

To hear the NetworkNewsAudio version, visit LINK

To read the original editorial, visit LINK

Soligenix Inc. is advancing HyBryte, its late-stage therapy for cutaneous T-cell lymphoma (CTCL), a rare and chronic cancer that primarily affects older adults. HyBryte has shown strong promise as a first-line treatment option for early-stage CTCL, a market estimated at nearly $1 billion globally, with 70% of that opportunity in the U.S. The therapy has already received orphan drug designations in both the U.S. and Europe, as well as FDA Fast Track status. Unlike traditional treatments that can take a year or more to show efficacy, HyBryte demonstrated statistically significant results in just six weeks in its initial phase 3 trial. A second confirmatory phase 3 study, FLASH2, is now underway in the U.S. and Europe and is designed to provide further validation of HyBryte’s safety and effectiveness, with top-line results expected in 2026.

HyBryte's safety profile stands out in a treatment space where many existing options carry significant side effects, including DNA damage and long-term carcinogenic risks. The therapy’s use of synthetic hypericin activated by non-carcinogenic visible light — rather than ultraviolet light — offers a safer alternative, especially for older patients. With minimal systemic absorption and strong responses across both patch and plaque lesions, HyBryte has the potential to redefine the standard of care for CTCL. Soligenix's advancements in this rare disease area highlight the growing urgency and opportunity in addressing complex conditions that disproportionately affect aging populations.

About Soligenix Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (“SGX301” or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (“SGX302”) into psoriasis, the company’s first-in-class innate defense regulator (“IDR”) technology, dusquetide (“SGX942”) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (“SGX945”) in Behçet’s disease.

The company’s Public Health Solutions business segment includes development programs for RiVax(R), its ricin toxin vaccine candidate, as well as its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), the company’s vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of Soligenix’s vaccine programs incorporates the use of its proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grants and contract funding from the National Institute of Allergy and Infectious Diseases (“NIAID”), the Defense Threat Reduction Agency (“DTRA”) and the Biomedical Advanced Research and Development Authority (“BARDA”).

For further information, visit the company’s website at Soligenix Inc.

About NetworkNewsAudio

NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we're watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.

For more information, visit: www.NetworkNewsAudio.com

NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public. With an ever-growing distribution network of more than 5,000 key syndication outlets across the nation, NNW cuts through the overload of information in today's markets bringing its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire is where news, content and information converge.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://NNW.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

AUSTIN, Texas, August 8, 2025 – via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas,” featuring Soligenix Inc. (NASDAQ: SNGX).

To hear the NetworkNewsAudio version, visit LINK

To read the original editorial, visit LINK

Soligenix Inc. is advancing HyBryte, its late-stage therapy for cutaneous T-cell lymphoma (CTCL), a rare and chronic cancer that primarily affects older adults. HyBryte has shown strong promise as a first-line treatment option for early-stage CTCL, a market estimated at nearly $1 billion globally, with 70% of that opportunity in the U.S. The therapy has already received orphan drug designations in both the U.S. and Europe, as well as FDA Fast Track status. Unlike traditional treatments that can take a year or more to show efficacy, HyBryte demonstrated statistically significant results in just six weeks in its initial phase 3 trial. A second confirmatory phase 3 study, FLASH2, is now underway in the U.S. and Europe and is designed to provide further validation of HyBryte’s safety and effectiveness, with top-line results expected in 2026.

HyBryte's safety profile stands out in a treatment space where many existing options carry significant side effects, including DNA damage and long-term carcinogenic risks. The therapy’s use of synthetic hypericin activated by non-carcinogenic visible light — rather than ultraviolet light — offers a safer alternative, especially for older patients. With minimal systemic absorption and strong responses across both patch and plaque lesions, HyBryte has the potential to redefine the standard of care for CTCL. Soligenix's advancements in this rare disease area highlight the growing urgency and opportunity in addressing complex conditions that disproportionately affect aging populations.

About Soligenix Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (“SGX301” or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (“SGX302”) into psoriasis, the company’s first-in-class innate defense regulator (“IDR”) technology, dusquetide (“SGX942”) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (“SGX945”) in Behçet’s disease.

The company’s Public Health Solutions business segment includes development programs for RiVax(R), its ricin toxin vaccine candidate, as well as its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), the company’s vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of Soligenix’s vaccine programs incorporates the use of its proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grants and contract funding from the National Institute of Allergy and Infectious Diseases (“NIAID”), the Defense Threat Reduction Agency (“DTRA”) and the Biomedical Advanced Research and Development Authority (“BARDA”).

For further information, visit the company’s website at Soligenix Inc.

About NetworkNewsAudio

NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we're watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.

For more information, visit: www.NetworkNewsAudio.com

NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public. With an ever-growing distribution network of more than 5,000 key syndication outlets across the nation, NNW cuts through the overload of information in today's markets bringing its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire is where news, content and information converge.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://NNW.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed with cancer every year. Despite significant progress made in treating the disease, there is still a desperate need — and an enormous market potential — for new and more effective cancer drugs. Calidi Biotherapeutics Inc. (NYSE American: CLDI) (Profile) is committed to developing a novel approach to treating cancer through the precise delivery of genetic medicines to both primary tumors and metastatic sites of disease. This cutting-edge platform, which harnesses engineered viruses that can target sites of cancer in the body and deliver potent genetic medicines to attack tumors, has the potential to revolutionize the way cancer is treated. And while cancer is the initial focus for Calidi, the company has also begun to assess the potential of this technology in other areas of large unmet need such as autoimmune disease. Calidi is joining an elite group of high-quality companies focused on making a difference in the world of cancer and genetic medicines, including Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), CG Oncology Inc. (NASDAQ: CGON), Roche (OTCQX: RHHBY) and Merck & Co. Inc. (NYSE: MRK).

To view the full editorial, visit https://nnw.fm/NwefQ

About Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage biotechnology company pioneering the development of targeted therapies that can deliver genetic medicines to sites of disease. The company’s proprietary Redtail platform represents a decade of development and expertise in designing viral vectors that can evade immune detection allowing for systemic delivery and distal sites of disease in oncology and, potentially, other indications. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent gene therapies to metastatic locations.

The lead candidate from the Redtail platform, currently in IND-enabling studies, targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need. Additionally, Calidi is developing protected virotherapies, in clinical-stage, for intratumoral and localized administration, focusing on a subset of injectable cancer indications.

For more information, visit the company’s website at www.CalidiBio.com

NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://nnw.fm/CLDI

About NetworkNewsAudio

NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.

For more information, visit: www.NetworkNewsAudio.com

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer

NetworkNewsWire
Austin, Texas
www.NetworkNewsWire.com
512.354.7000 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is powered by IBN

An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed with cancer every year. Despite significant progress made in treating the disease, there is still a desperate need — and an enormous market potential — for new and more effective cancer drugs. Calidi Biotherapeutics Inc. (NYSE American: CLDI) (Profile) is committed to developing a novel approach to treating cancer through the precise delivery of genetic medicines to both primary tumors and metastatic sites of disease. This cutting-edge platform, which harnesses engineered viruses that can target sites of cancer in the body and deliver potent genetic medicines to attack tumors, has the potential to revolutionize the way cancer is treated. And while cancer is the initial focus for Calidi, the company has also begun to assess the potential of this technology in other areas of large unmet need such as autoimmune disease. Calidi is joining an elite group of high-quality companies focused on making a difference in the world of cancer and genetic medicines, including Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), CG Oncology Inc. (NASDAQ: CGON), Roche (OTCQX: RHHBY) and Merck & Co. Inc. (NYSE: MRK).

To view the full editorial, visit https://nnw.fm/NwefQ

About Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage biotechnology company pioneering the development of targeted therapies that can deliver genetic medicines to sites of disease. The company’s proprietary Redtail platform represents a decade of development and expertise in designing viral vectors that can evade immune detection allowing for systemic delivery and distal sites of disease in oncology and, potentially, other indications. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent gene therapies to metastatic locations.

The lead candidate from the Redtail platform, currently in IND-enabling studies, targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need. Additionally, Calidi is developing protected virotherapies, in clinical-stage, for intratumoral and localized administration, focusing on a subset of injectable cancer indications.

For more information, visit the company’s website at www.CalidiBio.com

NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://nnw.fm/CLDI

About NetworkNewsAudio

NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.

For more information, visit: www.NetworkNewsAudio.com

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer

NetworkNewsWire
Austin, Texas
www.NetworkNewsWire.com
512.354.7000 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is powered by IBN

AUSTIN, Texas, June 17, 2025 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Harry Simeonidis, CEO of Intelligent Bio Solutions Inc. (NASDAQ: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions.

During the interview, Simeonidis provided an overview of Intelligent Bio Solutions’ core offering and strategic direction.

“We bring a unique technology to the drug screening market,” he explained. “We have a product that detects drugs from the sweat on the top of your fingertips. It’s a whole new way of doing drug screening for people who come to work every single day.”

Simeonidis emphasized the company’s rapid expansion, noting early traction in the U.K. and current deployment across roughly 20 countries. “We’re a non-invasive technology company expanding globally with a lot of growth and revenue,” he said. “We’ve submitted our FDA application, and once we clear that, we expect to be in the U.S. in the second half of the year.”

He described the fingerprint-based test as faster, simpler and more affordable than traditional methods. “You can screen an employee before they actually start work — within 10 minutes,” he noted. “It’s a total game changer.”

Looking ahead, Intelligent Bio Solutions aims to scale through partnerships with U.S. distributors and labs. “They know the customers, they have the install base, and they know how to navigate the market,” Simeonidis said. “Once we get FDA clearance, we’ll increase our marketing campaigns. Once people know about the product, the adoption rate is very fast.”

Join IBN’s Carmel Fisher and Harry Simeonidis, President and CEO of Intelligent Bio Solutions, to learn more about the company’s entry into the U.S. market, plans for FDA clearance and how its fingerprint-based drug screening platform is reshaping workplace safety.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under 10 minutes, this technology would be a valuable tool for employers in safety-critical industries. The company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.

For more information, visit the company’s website at www.IBS.inc

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

AUSTIN, Texas, June 17, 2025 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Harry Simeonidis, CEO of Intelligent Bio Solutions Inc. (NASDAQ: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions.

During the interview, Simeonidis provided an overview of Intelligent Bio Solutions’ core offering and strategic direction.

“We bring a unique technology to the drug screening market,” he explained. “We have a product that detects drugs from the sweat on the top of your fingertips. It’s a whole new way of doing drug screening for people who come to work every single day.”

Simeonidis emphasized the company’s rapid expansion, noting early traction in the U.K. and current deployment across roughly 20 countries. “We’re a non-invasive technology company expanding globally with a lot of growth and revenue,” he said. “We’ve submitted our FDA application, and once we clear that, we expect to be in the U.S. in the second half of the year.”

He described the fingerprint-based test as faster, simpler and more affordable than traditional methods. “You can screen an employee before they actually start work — within 10 minutes,” he noted. “It’s a total game changer.”

Looking ahead, Intelligent Bio Solutions aims to scale through partnerships with U.S. distributors and labs. “They know the customers, they have the install base, and they know how to navigate the market,” Simeonidis said. “Once we get FDA clearance, we’ll increase our marketing campaigns. Once people know about the product, the adoption rate is very fast.”

Join IBN’s Carmel Fisher and Harry Simeonidis, President and CEO of Intelligent Bio Solutions, to learn more about the company’s entry into the U.S. market, plans for FDA clearance and how its fingerprint-based drug screening platform is reshaping workplace safety.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under 10 minutes, this technology would be a valuable tool for employers in safety-critical industries. The company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.

For more information, visit the company’s website at www.IBS.inc

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Gareth Sheridan, CEO of Nutriband Inc.

AUSTIN, Texas, May 27, 2025 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Gareth Sheridan, Co-Founder and CEO of Nutriband Inc. (NASDAQ: NTRB), a company engaged in the development of a portfolio of transdermal pharmaceutical products.

During the interview, Sheridan provided an introduction to Nutriband’s business model.

“We’re a pharmaceutical company specifically focused on transdermal technology… Our core focus is on a segment of the industry that has been overlooked and underrepresented for quite some time now – adequate pain management in the transdermal space. We’re all familiar and aware of the opiate scandals over the last 10 years and the fallout from that. It resulted in a very negative opiate stigma surrounding all of pain management, but the real fallout was actually a lack of adequate care for pain patients. We’re tackling this head-on with our AVERSA™ technology.”

“It is a platform tech that we’ve developed internally that can be applied to any pain patch medication with the goal of making them very difficult to abuse. Because of that, we’re also making these medications accessible to patients who have had their access cut in recent years… Our first application for AVERSA is a fentanyl patch. Fentanyl is a scary word in a lot of people’s vocabulary, but, when used correctly, fentanyl is a very effective pain medication… Unfortunately, because of the fallout from the opiate scandals we’ve seen in recent years, these types of products have been faced with a major reluctance when it comes to prescribers, insurance companies, and payers. Nobody wants to deal with the liability issues associated with these products.”

“You saw companies actually getting out of the space and moving on, but the people who felt the fallout from this were actually the pain patient themselves. Prescription rates are down an astronomical number since their height in 2016, when fentanyl patches, for example, were about a $4 billion a year market. They're under $1 billion a year now in terms of market size, but the patient population requiring access to these medications has not reduced by 75%. We're looking at a massive disconnect between adequate management and adequate care for patients on prescription rates. That's something that we'll tackle head-on with our AVERSA technology.”

Join IBN’s Carmel Fisher and Gareth Sheridan, Co-Founder and CEO of Nutriband, to learn more about the company’s development pipeline, as well as the unique ways AVERSA helps address abuse of pain medication.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Nutriband Inc.

Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

For more information, visit the company’s website at www.Nutriband.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

AUSTIN, Texas, May 27, 2025 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Gareth Sheridan, Co-Founder and CEO of Nutriband Inc. (NASDAQ: NTRB), a company engaged in the development of a portfolio of transdermal pharmaceutical products.

During the interview, Sheridan provided an introduction to Nutriband’s business model.

“We’re a pharmaceutical company specifically focused on transdermal technology… Our core focus is on a segment of the industry that has been overlooked and underrepresented for quite some time now – adequate pain management in the transdermal space. We’re all familiar and aware of the opiate scandals over the last 10 years and the fallout from that. It resulted in a very negative opiate stigma surrounding all of pain management, but the real fallout was actually a lack of adequate care for pain patients. We’re tackling this head-on with our AVERSA™ technology.”

“It is a platform tech that we’ve developed internally that can be applied to any pain patch medication with the goal of making them very difficult to abuse. Because of that, we’re also making these medications accessible to patients who have had their access cut in recent years… Our first application for AVERSA is a fentanyl patch. Fentanyl is a scary word in a lot of people’s vocabulary, but, when used correctly, fentanyl is a very effective pain medication… Unfortunately, because of the fallout from the opiate scandals we’ve seen in recent years, these types of products have been faced with a major reluctance when it comes to prescribers, insurance companies, and payers. Nobody wants to deal with the liability issues associated with these products.”

“You saw companies actually getting out of the space and moving on, but the people who felt the fallout from this were actually the pain patient themselves. Prescription rates are down an astronomical number since their height in 2016, when fentanyl patches, for example, were about a $4 billion a year market. They're under $1 billion a year now in terms of market size, but the patient population requiring access to these medications has not reduced by 75%. We're looking at a massive disconnect between adequate management and adequate care for patients on prescription rates. That's something that we'll tackle head-on with our AVERSA technology.”

Join IBN’s Carmel Fisher and Gareth Sheridan, Co-Founder and CEO of Nutriband, to learn more about the company’s development pipeline, as well as the unique ways AVERSA helps address abuse of pain medication.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Nutriband Inc.

Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

For more information, visit the company’s website at www.Nutriband.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

AUSTIN, Texas, May 7, 2025 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Christopher Schaber, Chairman, President, and CEO of Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs.

During the interview, Schaber provided an introduction to Soligenix’s business model.

“I think what makes Soligenix unique is that we have two areas of focus. Our Specialized BioTherapeutics segment is focused on small molecules in oncology, and inflammation. Through a separate Public Health Solutions segment of our business that’s been funded entirely by the U.S. government – in excess of $60 million in non-dilutive funding over the years – we focus predominantly on heat-stable vaccines for emerging infectious diseases and biothreats. Through these segments, we’ve been able to build out a more robust pipeline than you would typically see for a company our size, with multiple ‘shots on goal’ to mitigate risk.”

Schaber next discussed how Soligenix is adapting to current uncertainties surrounding federal research funding and priorities.

“We focus on what we can control – our primary programs that we’re actively enrolling. We have three clinical studies, including one confirmatory Phase 3. We’re focusing our time, resources, and effort there, and if additional non-dilutive government funding comes that can support our public health business segment, then we will continue to advance that. In times like this, you need to focus in on those things that you can get across the finish line as quickly as possible.”

“Beyond the capital that we’ve raised to support the clinical studies we’re pursuing, we are always submitting government grant contracts to get additional funding. That remains a piece of our business that we really focus on. Another thing that we’re really focused on in the near term is business development opportunities and looking at all strategic options. As you would imagine with a late-stage pipeline like ours and active programs – especially a confirmatory study in a rare cancer – there is interest. We are in a number of discussions that could range anywhere from regional partnership to M&A.”

Join IBN’s Carmel Fisher and Dr. Christopher Schaber, Chairman, President, and CEO of Soligenix, to learn more about the company’s HyBryte™ clinical programs, as well as the key milestones on Soligenix’s radar for the balance of 2025.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Soligenix Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (“SGX301” or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide.

For more information, visit the company’s website at www.Soligenix.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

AUSTIN, Texas, May 7, 2025 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Christopher Schaber, Chairman, President, and CEO of Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs.

During the interview, Schaber provided an introduction to Soligenix’s business model.

“I think what makes Soligenix unique is that we have two areas of focus. Our Specialized BioTherapeutics segment is focused on small molecules in oncology, and inflammation. Through a separate Public Health Solutions segment of our business that’s been funded entirely by the U.S. government – in excess of $60 million in non-dilutive funding over the years – we focus predominantly on heat-stable vaccines for emerging infectious diseases and biothreats. Through these segments, we’ve been able to build out a more robust pipeline than you would typically see for a company our size, with multiple ‘shots on goal’ to mitigate risk.”

Schaber next discussed how Soligenix is adapting to current uncertainties surrounding federal research funding and priorities.

“We focus on what we can control – our primary programs that we’re actively enrolling. We have three clinical studies, including one confirmatory Phase 3. We’re focusing our time, resources, and effort there, and if additional non-dilutive government funding comes that can support our public health business segment, then we will continue to advance that. In times like this, you need to focus in on those things that you can get across the finish line as quickly as possible.”

“Beyond the capital that we’ve raised to support the clinical studies we’re pursuing, we are always submitting government grant contracts to get additional funding. That remains a piece of our business that we really focus on. Another thing that we’re really focused on in the near term is business development opportunities and looking at all strategic options. As you would imagine with a late-stage pipeline like ours and active programs – especially a confirmatory study in a rare cancer – there is interest. We are in a number of discussions that could range anywhere from regional partnership to M&A.”

Join IBN’s Carmel Fisher and Dr. Christopher Schaber, Chairman, President, and CEO of Soligenix, to learn more about the company’s HyBryte™ clinical programs, as well as the key milestones on Soligenix’s radar for the balance of 2025.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Soligenix Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (“SGX301” or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide.

For more information, visit the company’s website at www.Soligenix.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

AUSTIN, Texas, January 14, 2025 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Shane Speirs, CEO of Adageis, a healthcare technology company dedicated to revolutionizing patient care through innovative solutions.

During the interview, Speirs provided an introduction to Adageis’ business model.

“Healthcare is a complicated place, and navigating the system is extremely difficult for patients,” Speirs explained. “On the healthcare delivery side, it's also tough. Classically, there have been different reimbursement methods for healthcare services in the United States, but many agree the future is value-based care.”

“What Adageis does is provide a simple solution to healthcare organizations – ranging from large, multi-state, multi-specialty healthcare groups to independent practices across the country. We offer a solution that meets everyone's needs, helping providers and organizations drive revenue by delivering high-quality care, which everyone can align with… Much of the value in value-based care comes from providing proper documentation to patients and being proactive with screenings. We provide an easy solution for practices to indicate the metrics needed for patients, to provide high-quality care while maximizing incentive dollars.”

“One of the major challenges in the marketplace is the sheer complexity – there are over 100 insurance companies with more than 1,000 plans in the Phoenix area alone. Each has different measures and unique documentation requirements… Adageis has a solution that integrates with nearly 100 electronic health record systems, overlaying existing platforms to provide easy-to-read measures tailored to each patient’s insurance.”

Join IBN’s Carmel Fisher and Shane Speirs, CEO of Adageis, to explore the company’s sustained efforts to maintain seamless interoperability while implementing cutting-edge, AI-driven analytics.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Adageis

Adageis is a healthcare technology innovator focused on addressing inefficiencies in care delivery through AI and machine learning. Its solutions empower healthcare providers and healthcare organizations to enhance patient outcomes, streamline operations, and drive increased revenue through meeting the demands of value-based care. By integrating advanced technologies with minimal disruption, Adageis remains a leader in driving meaningful change across the healthcare sector.

For more information, visit the company’s website at www.Adageis.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

AUSTIN, Texas, January 14, 2025 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Shane Speirs, CEO of Adageis, a healthcare technology company dedicated to revolutionizing patient care through innovative solutions.

During the interview, Speirs provided an introduction to Adageis’ business model.

“Healthcare is a complicated place, and navigating the system is extremely difficult for patients,” Speirs explained. “On the healthcare delivery side, it's also tough. Classically, there have been different reimbursement methods for healthcare services in the United States, but many agree the future is value-based care.”

“What Adageis does is provide a simple solution to healthcare organizations – ranging from large, multi-state, multi-specialty healthcare groups to independent practices across the country. We offer a solution that meets everyone's needs, helping providers and organizations drive revenue by delivering high-quality care, which everyone can align with… Much of the value in value-based care comes from providing proper documentation to patients and being proactive with screenings. We provide an easy solution for practices to indicate the metrics needed for patients, to provide high-quality care while maximizing incentive dollars.”

“One of the major challenges in the marketplace is the sheer complexity – there are over 100 insurance companies with more than 1,000 plans in the Phoenix area alone. Each has different measures and unique documentation requirements… Adageis has a solution that integrates with nearly 100 electronic health record systems, overlaying existing platforms to provide easy-to-read measures tailored to each patient’s insurance.”

Join IBN’s Carmel Fisher and Shane Speirs, CEO of Adageis, to explore the company’s sustained efforts to maintain seamless interoperability while implementing cutting-edge, AI-driven analytics.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Adageis

Adageis is a healthcare technology innovator focused on addressing inefficiencies in care delivery through AI and machine learning. Its solutions empower healthcare providers and healthcare organizations to enhance patient outcomes, streamline operations, and drive increased revenue through meeting the demands of value-based care. By integrating advanced technologies with minimal disruption, Adageis remains a leader in driving meaningful change across the healthcare sector.

For more information, visit the company’s website at www.Adageis.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast showcases fast-paced interviews with industry experts pioneering pharmaceutical and biotech advancements. The latest episode features Dr. Maria Maccecchini, Founder, President, and CEO of Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD).

In this episode, Dr. Maccecchini discusses the company’s recent meetings with the U.S. Food and Drug Administration (FDA), which resulted in clearance to initiate pivotal Phase 3 studies of buntanetap in early-stage AD patients.

“To date, we have conducted four small studies in Alzheimer’s, and now the FDA has granted us clearance to do the very last study, which is really a confirmation of the study we just completed,” she explains. “Once we have that confirmation, we’ll be able to submit a request for market approval.”

“We are so excited about this data, because buntanetap is good in both Alzheimer’s and Parkinson’s. The reason that we believe it works in a number of neurodegenerative diseases is that it attacks more than one neurotoxic protein. What pharma has done to date is attack mostly amyloid-beta plaques. If you attack plaques, you get a small response. However, if you attack more than one toxic protein, and in the brain of an Alzheimer’s patient there are at least four toxic proteins, you have a better outcome.”

“Our limited data in the three-month study we just did shows that our drug has better efficacy than the existing drugs on the market, at least in the short term. We have differentiated ourselves from other approaches with our mechanism of action for over 10 years, but the question is, does it improve cognition while being different? The exciting thing is that the FDA believes it's worth reproducing the data we have to prove that, in fact, it works. The FDA always wants you to have two studies, and this new pivotal Phase 3 studies will serve as a confirmation of the previous findings.”

Join IBN’s Carmel Fisher and Dr. Maria Maccecchini, Founder, President, and CEO of Annovis Bio, to learn more about the company’s strategy to move rapidly toward a potential New Drug Application (NDA) filing following commencement of its upcoming Phase 3 study.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Annovis Bio Inc.

Headquartered in Malvern, Pennsylvania, Annovis Bio Inc. is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast showcases fast-paced interviews with industry experts pioneering pharmaceutical and biotech advancements. The latest episode features Dr. Maria Maccecchini, Founder, President, and CEO of Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD).

In this episode, Dr. Maccecchini discusses the company’s recent meetings with the U.S. Food and Drug Administration (FDA), which resulted in clearance to initiate pivotal Phase 3 studies of buntanetap in early-stage AD patients.

“To date, we have conducted four small studies in Alzheimer’s, and now the FDA has granted us clearance to do the very last study, which is really a confirmation of the study we just completed,” she explains. “Once we have that confirmation, we’ll be able to submit a request for market approval.”

“We are so excited about this data, because buntanetap is good in both Alzheimer’s and Parkinson’s. The reason that we believe it works in a number of neurodegenerative diseases is that it attacks more than one neurotoxic protein. What pharma has done to date is attack mostly amyloid-beta plaques. If you attack plaques, you get a small response. However, if you attack more than one toxic protein, and in the brain of an Alzheimer’s patient there are at least four toxic proteins, you have a better outcome.”

“Our limited data in the three-month study we just did shows that our drug has better efficacy than the existing drugs on the market, at least in the short term. We have differentiated ourselves from other approaches with our mechanism of action for over 10 years, but the question is, does it improve cognition while being different? The exciting thing is that the FDA believes it's worth reproducing the data we have to prove that, in fact, it works. The FDA always wants you to have two studies, and this new pivotal Phase 3 studies will serve as a confirmation of the previous findings.”

Join IBN’s Carmel Fisher and Dr. Maria Maccecchini, Founder, President, and CEO of Annovis Bio, to learn more about the company’s strategy to move rapidly toward a potential New Drug Application (NDA) filing following commencement of its upcoming Phase 3 study.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Annovis Bio Inc.

Headquartered in Malvern, Pennsylvania, Annovis Bio Inc. is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

The BioMedWire Podcast features fast-paced interviews with experts guiding the next wave of pharmaceutical and biotech innovation. The latest episode features Amir Reichman, CEO of Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology biological products and on providing CDMO services through its Scinai Bioservices business unit.

To begin the interview, Reichman discussed Scinai Immunotherapeutics’ business model.

“Scinai is developing its own innovative pipeline of biological therapeutic products based on a unique technology of VHH single domain antibodies originating from alpacas,” he said. “The antibodies are licensed from the Max Planck Institute and the University Medical Centre Göttingen, both in Germany. The two principal investigators with whom who we work are Professor Dirk Görlich and Professor Matthias Dobbelstein.”

Join IBN’s Carmel Fisher and Amir Reichman, CEO of Scinai Immunotherapeutics, to learn more about the company’s recent milestones.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

 

 

The BioMedWire Podcast features fast-paced interviews with experts guiding the next wave of pharmaceutical and biotech innovation. The latest episode features Amir Reichman, CEO of Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology biological products and on providing CDMO services through its Scinai Bioservices business unit.

To begin the interview, Reichman discussed Scinai Immunotherapeutics’ business model.

“Scinai is developing its own innovative pipeline of biological therapeutic products based on a unique technology of VHH single domain antibodies originating from alpacas,” he said. “The antibodies are licensed from the Max Planck Institute and the University Medical Centre Göttingen, both in Germany. The two principal investigators with whom who we work are Professor Dirk Görlich and Professor Matthias Dobbelstein.”

Join IBN’s Carmel Fisher and Amir Reichman, CEO of Scinai Immunotherapeutics, to learn more about the company’s recent milestones.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

 

The latest episode features John Climaco, CEO of CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system.

To begin the interview, Climaco discussed CNS Pharmaceuticals’ business model, including the company’s recent announcement of an exclusive in-license agreement to expand its development pipeline.

“We are an oncology drug development company. Specifically, our space is neuro-oncology – cancers of the brain and the central nervous system. Traditionally, these are some of the most difficult and deadly cancers,” he said. “They are very challenging to treat, because they lie beyond the blood-brain barrier, which is this very specialized network of cells that protects the most important organ in the body. It's very hard to get drugs and treatments to the brain when you have tumors growing in it, so that is really what we specialize in.”

“We have a very exciting compound called Berubicin. It's a first-in-class drug that penetrates the blood-brain barrier and treats brain cancer. This is in a late stage, designed to be pivotal trial, with over 250 patients in the United States and Europe currently enrolled. It'll be reading top-line data in the first half of next year, so we're very excited about that. We've been working on Berubicin since the company's inception back in 2017.”

“Our recent news is equally exciting. After many years of searching and diligence and evaluating over 200 different compounds for potential in-license, we settled on an amazing drug called TPI-287, which is a novel abeotaxane of the taxane family. This is also a unique blood-brain barrier penetrant drug that was specifically designed to treat these very difficult brain cancers, such as glioblastoma. This drug has already been used in 350 patients in a series of phase one studies. We are just getting started on planning what will be another designed to be pivotal study for this very exciting drug.”

Join IBN’s Carmel Fisher and John Climaco, CEO of CNS Pharmaceuticals Inc., to learn more about what sets Berubicin, as well as the company’s new TPI-287 candidate, apart from anything else in development for glioblastoma.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

The latest episode features John Climaco, CEO of CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system.

To begin the interview, Climaco discussed CNS Pharmaceuticals’ business model, including the company’s recent announcement of an exclusive in-license agreement to expand its development pipeline.

“We are an oncology drug development company. Specifically, our space is neuro-oncology – cancers of the brain and the central nervous system. Traditionally, these are some of the most difficult and deadly cancers,” he said. “They are very challenging to treat, because they lie beyond the blood-brain barrier, which is this very specialized network of cells that protects the most important organ in the body. It's very hard to get drugs and treatments to the brain when you have tumors growing in it, so that is really what we specialize in.”

“We have a very exciting compound called Berubicin. It's a first-in-class drug that penetrates the blood-brain barrier and treats brain cancer. This is in a late stage, designed to be pivotal trial, with over 250 patients in the United States and Europe currently enrolled. It'll be reading top-line data in the first half of next year, so we're very excited about that. We've been working on Berubicin since the company's inception back in 2017.”

“Our recent news is equally exciting. After many years of searching and diligence and evaluating over 200 different compounds for potential in-license, we settled on an amazing drug called TPI-287, which is a novel abeotaxane of the taxane family. This is also a unique blood-brain barrier penetrant drug that was specifically designed to treat these very difficult brain cancers, such as glioblastoma. This drug has already been used in 350 patients in a series of phase one studies. We are just getting started on planning what will be another designed to be pivotal study for this very exciting drug.”

Join IBN’s Carmel Fisher and John Climaco, CEO of CNS Pharmaceuticals Inc., to learn more about what sets Berubicin, as well as the company’s new TPI-287 candidate, apart from anything else in development for glioblastoma.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine